News and Press Releases

Contact Veristat Now

Request A Proposal

Contact Us

Veristat to Assist on Adaptive Enrichment Design Trial for Verastem’s Defactinib in Mesothelioma

Input Will Drive Trial Design for Lead Cancer Stem Cell-Targeting Program

 

September 10, 2013  -  Veristat, a leading, Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem, Inc. (NASDAQ: VSTM).

Read More

Veristat’s Collaboration with Aegerion Contributes to FDA Approval of Juxtapid™

Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid

 

Read More

Variance Development Partners Makes a Growth Investment in Veristat

Investment Will Enable Veristat to Further Enhance its Market Leadership Position and Provide Resources for Growth

Veristat, a leading Clinical Research Organization (CRO) announced today that Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms providing services to developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

Read More

Search

    Topics

    see all

    Follow Us

    Monthly Archives

    see all
    • Privacy Policy
    • ©2006 - 2021 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.